Shares of Freenome (NASDAQ:FRNM – Get Free Report) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $17.25 and last traded at $16.6840, with a volume of 54098 shares. The stock had previously closed at $16.29.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on the company. Guggenheim initiated coverage on Freenome in a research report on Thursday, August 20th. They issued a “buy” rating and a $21.00 price objective for the company. BTIG Research assumed coverage on Freenome in a research report on Monday, August 17th. They set a “buy” rating and a $17.00 target price on the stock. Jefferies Financial Group started coverage on Freenome in a research note on Monday, August 17th. They issued a “buy” rating and a $17.00 price target for the company. TD Cowen began coverage on Freenome in a report on Tuesday, August 18th. They issued a “buy” rating and a $17.00 price target for the company. Finally, Weiss Ratings assumed coverage on shares of Freenome in a report on Monday, August 24th. They set a “sell (d+)” rating on the stock. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Freenome has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.
Get Our Latest Report on Freenome
Freenome Trading Up 3.7%
Freenome Company Profile
Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. Its approach combines artificial intelligence with multiomics analysis, examining biological signals in blood, including circulating tumor material and other molecular indicators.
The company has focused on noninvasive screening tests for colorectal cancer and other cancers. Freenome’s products remain in development and are being evaluated through clinical research and validation studies; the company’s tests are not described here as broadly approved diagnostic products.
Founded in 2014 and headquartered in the United States, Freenome has worked with healthcare providers, research organizations and pharmaceutical companies to advance its screening technology.
Recommended Stories
- Five stocks we like better than Freenome
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
- Braze Beat Expectations—Now 2 SaaS Peers Are in Focus
- 3 Zero-Fee ETFs Worth More Than Their Cost
- 3 Nimble Free Cash Flow Names With Light Assets
Receive News & Ratings for Freenome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freenome and related companies with MarketBeat.com's FREE daily email newsletter.
